[Klinefelter syndrome and acute myeloblastic leukaemia].
Bellaaj
Hatem
H
Service d'hématologie, Hôpital Hédi Chaker, Sfax, TN-3029, Tunisie. hatem.bellaaj@rns.tn
Sandi
Halima Sennana
HS
Kammoun
Hassen
H
Kallel
Choumous
C
Kassar
Olfa
O
Elloumi
Moez
M
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001856:Bone Marrow Examination; D002879:Chromosomes, Human, Pair 10; D002898:Chromosomes, Human, Pair 8; D003561:Cytarabine / Q000627:therapeutic use; D003582:Cytogenetics; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D007713:Klinefelter Syndrome / Q000175:diagnosis* / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D008297:Male; D014314:Trisomy
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D015255:Idarubicin